Hagop Kantarjian, MD of MD Anderson Cancer Center discusses phase III RATIFY trial 7+3 chemo plus Midostaurin or placebo in FLT3 mutated AML at the Scripps 36th Annual Conference: Clinical Hematology and Oncology in San Diego.
Advertisement
[the_ad id="32629"]
Phase III RATIFY trial 7+3 chemo plus Midostaurin or placebo in FLT3 mutated AML – Hagop Kantarjian, MD
By Editor